Amgen: Zarxio Lawsuit 'Poor Vehicle' To Interpret BPCIA
This article was originally published in Scrip
Executive Summary
The US Supreme Court should decline Sandoz Inc.'s request to review a ruling by the US Court of Appeals for the Federal Circuit involving the Biologics Price Competition and Innovation Act (BPCIA) because the case is a "poor vehicle" for the high-court's first interpretation of the 2010 biosimilars law, Amgen Inc. argued in a new brief.